Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 158 matching trials from the live ClinicalTrials.gov search.
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Not listed
Lead sponsor
Alcon Research
Industry
Eligibility
55 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Age-related Macular Degeneration
Interventions
LFG316
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
Conditions
Age Related Macular Degeneration, Geographic Atrophy
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Oakland, California • Jackson, Michigan
Conditions
Macular Degeneration, Age-Related, Geographic Atrophy
Interventions
Galegenimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Bakersfield, California • Encino, California • Fullerton, California + 43 more
Conditions
Age-Related Macular Degeneration
Interventions
OT-551, vehicle placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
VV-14295
Genetic
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Erie, Pennsylvania
Conditions
Visual Acuity, Geographic Atrophy, Macular Degeneration
Interventions
CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
Drug · Device
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Arcadia, California • Chicago, Illinois • Lexington, Kentucky + 5 more
Conditions
Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Davis, California • Palo Alto, California • Sacramento, California + 7 more
Completed Not applicable Interventional Results available

The Zeaxanthin and Visual Function Study

NCT00564902
Conditions
Age Related Macular Degeneration, Cognition Disorders
Interventions
3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
Drug · Dietary Supplement
Lead sponsor
Chrysantis, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Terminated Phase 2 Interventional Accepts healthy volunteers

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

NCT03451500
Conditions
Age Related Macular Degeneration
Interventions
carbidopa-levodopa
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Conditions
Age-related Macular Degeneration
Interventions
Subcutaneous elamipretide through the elamipretide delivery system, Subcutaneos placebo through the elamipretide delivery system
Combination Product
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT

NCT03688243
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Conditions
Geographic Atrophy
Interventions
NGM621
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
Conditions
Macular Degeneration
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Advanced Age-Related Macular Degeneration

NCT01445548
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
56 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Geographic Atrophy
Interventions
ANX007, Sham comparator
Drug · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 39 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Conditions
Age-Related Macular Degeneration
Interventions
HuCNS-SC sub-retinal transplantation
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Campbell, California + 9 more
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of ALK-001 in Geographic Atrophy

NCT03845582
Conditions
Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
Interventions
ALK-001 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more
Conditions
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Interventions
BS01, Sham procedure control
Biological · Other
Lead sponsor
Bionic Sight LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland